Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
José L. Casado(Instituto Cajal), Alejandro Vallejo(Instituto Ramón y Cajal de Investigación Sanitaria), Marina Fernández-Escribano(Hospital Universitario Ramón y Cajal), Tamara Velasco(Hospital Universitario Ramón y Cajal), Pilar Vizcarra(Universidad de Alcalá), Beatriz Romero‐Hernández(Instituto de Salud Carlos III), Sara De Martin(University of Padua), Héctor Velasco(Hospital Universitario Ramón y Cajal), Mario Rodríguez-Domínguez(Instituto Cajal), Adrián Martín-Hondarza(Hospital Universitario Ramón y Cajal), Johannes Häemmerle(Hospital Universitario Ramón y Cajal)
Cited by 18
Related Papers
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals
|Mucosal Immunology|2014|332
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
|HIV Medicine|2020|166
The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects
|Mucosal Immunology|2016|133